Abstract: i n d i a n j o u r n a l o f t u b e r c u l o s i s 6 7 ( 2 0 2 0 ) 4 4 8 e4 5 1 Available online at www.sciencedirect.com ScienceDirect journal homepage: http://www.journals.elsevier.com/ indian-journal-of-tuberculosis/ Letter to the Editor White paper on Ivermectin as a potential therapy for COVID-19 abstract Keywords: A group of senior doctors with vast clinical experience met on 19th July’20 under the aegis Antiviral of Academy of Advanced Medical Education. The panel looked at Ivermectin, one of the old Coronavirus molecule and evaluated it's use in COVID 19 (Novel Coronavirus Disease 2019) manage- Infection ment. After critical panel discussion, all the attending doctors came to a conclusion that Pandemic Ivermectin can be a potential molecule for prophylaxis and treatment of people infected PCR with Coronavirus, owing to its anti-viral properties coupled with effective cost, availability SARS-CoV-2 and good tolerability and safety. © 2020 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved. 1. Executive summary SARS-CoV-2, a small 100 nm virus has emerged as an elusive foe, threatening mankind. Currently India is placed 3rd in terms of number of reported cases which warrants newer therapeutic treatment options that are widely available, affordable, effective and safe. There are newer drugs on the horizon which have been recommended though with very limited experience & devoid of enough data about safety and efficacy.1 These newer options are neither easily available nor affordable. We have revisited some of the old molecules & have found Ivermectin, originally introduced as an anthelmintic to be an effective, safe and affordable therapeutic option in Indian settings for prevention and treatment of COVID-19.2 Recent research has shown that Ivermectin possesses strong anti-viral properties.3 It has potential to convert RTPCR negative quickly.4 It can be used across the severity of COVID-19 especially in early viremic phase.5 It can be combined with other molecules of interest, like Hydroxychloroquine, azithromycin, doxycycline.6 Ivermectin is affordable, easily available, and safe without any major side effects.5 This white paper is an attempt to propose Ivermectin, a strong antiviral drug as a therapeutic option in the prevention and treatment of mild, moderate and severe cases of COVID-19. A group of senior doctors with vast experience in the management of COVID-19 got together on 19th July’20 under the leadership of Prof Dr V. K. Arora, Prof. Dr D. Behera, Prof. Dr Suryakant Tripathy, Dr. MohanKumar Thekkinkattil, Dr. Agam Vora, Dr. Vasant Nagvekar, Lt Gen (Rtd) Dr. B.N.B.M Prasad, Dr. K.S. Satish, Dr. V.K.Singh, Dr. Mangesh Tiwaskar, Dr. Parthiv Mehta, Dr. P. Sarat Singh, Dr. Narayana Pradeep, Dr. Rahul Mayekar and Dr. Bhupesh Dewan, under the auspices of Academy of Advanced Medical Education. Many of the attending doctors shared their personal experience of using Ivermectin successfully with very good results in their patients. The group, at the end of the discussion, proposed the following consensus statement: “Ivermectin in the dose of 12 mg BD alone or in combination with other therapy for 5 to 7 days may be considered as safe therapeutic option for mild moderate or severe cases of Covid-19 infection. It is cost effective especially when the other drugs are very costly & not easily available”. However, the group strongly feels the urgent need for a well-designed..